{"Clinical Trial ID": "NCT00834678", "Intervention": ["INTERVENTION 1:", "Bendamustine and Erlotinib", "Dose I participants received 100 mg/m^2 IV of Bendamustine on days 1 and 2 and 100 mg PO of Erlotinib on days 5 to 21 of each 28-day cycle.", "Dose level II participants received 120 mg/m^2 IV of Bendamustine on days 1 and 2 and 150 mg PO of Erlotinib on days 5 to 21 of each 28-day cycle."], "Eligibility": ["CHARACTERISTICS OF DISEASE:", "Breast cancer, confirmed histologically, meets 1 of the following criteria:", "Stage IIIB or IIIC non-resectable disease rate", "Stage IV typology", "- Must be negative for all of the following:", "Estrogen receiver (< 10%)", "Progesterone receptor (<10%)", "HER-2 (negative POISSON, IHC 0 - 1+, or IHC +2 with negative FISH)", "A measurable or evaluable disease", "No symptomatic or progressive CNS metastases (central nervous system)", "The CNS metastases previously treated are allowed provided that all of the following criteria are met:", "At least 8 weeks since pre-brain or CNS metastases radiation", "No concomitant steroids", "No leptomenergic disease", "CHARACTERISTICS OF PATIENTS:", "\u2022 Menopausal status not specified", "ECOG (Eastern Cooperative Oncology Group) Statement of Operations 0-2", "Life expectancy 6 months", "WBC > 1500/mm3", "Number of platelets > 100 000/mm3", "creatinine clearance > 40 mL/min", "- Normal electrolytes (i.e. normal electrolytes Na, K and Ca; minor deviations are allowed if they do not affect patient safety in the clinical judgment of the treating physician)", "Bilirubine 1.5 times the upper limit of normal (ULN)", "ALT and AST 2.5 times LSN ( 5 times LSN in the presence of documented liver metastases)", "- Alcaline phosphatase 2.5 times ULN ( 5 times ULN in the presence of liver or bone metastases)", "No pregnancy or breast-feeding", "Fertile patients should use effective contraception against barriers.", "No uncontrolled intercurrent disease", "No active infection requiring systemic treatment", "- Capable of swallowing oral medicines and without previous medical problems or surgical procedures that may interfere with the absorption of oral medicines, including:", "Uncontrolled nausea, vomiting or diarrhoea", "Lack of physical integrity of the upper gastrointestinal tract", "Malabsorption syndrome", "No known hypersensitivity to bendamustin hydrochloride, mannitol or erlotinib hydrochloride", "No prior malignancy in the last 5 years, except for properly treated basal cell or squamous skin carcinoma, or for properly treated stage I-II cancer for which the patient is in complete remission", "THERAPE PRIOR CONCURENT:", "See Disease Characteristics", "For all acute toxicity, prior adjuvant or neoadjuvant chemotherapy and prior chemotherapy regimen in the metastatic context were allowed.", "No previous bendamustin hydrochloride or treatment with EGFR", "No other concomitant antineoplastic therapy including radiation therapy, chemotherapy, biological therapy, hormone therapy, immunotherapy, gene therapy and surgery", "The administration of intravenous bisphosphonates is permitted.", "No concomitant antiretroviral therapy for HIV-positive patients", "No other competing search agent"], "Results": ["Performance measures:", "Maximum tolerated dose of bendamustin hydrochloride (phase I)", "The 28-day cycle included intravenous bendamustin on days 1 and 2.", "Time limit: Up to two years", "Results 1:", "Title of the arm/group: Bendamustine and Erlotinib", "Arm/Group Description: Dose I participants received 100 mg/m^2 IV of Bendamustine on days 1 and 2 and 100 mg PO of Erlotinib on days 5 to 21 of each 28-day cycle.", "Dose level II participants received 120 mg/m^2 IV of Bendamustine on days 1 and 2 and 150 mg PO of Erlotinib on days 5 to 21 of each 28-day cycle.", "Total number of participants analysed: 11", "Type of measurement: Number", "Unit of measurement: mg/m2 120"], "Adverse Events": ["Undesirable Events 1:", "Total: 3/11 (27.27 per cent)", "3/11 (27.27 per cent)"]}